Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastiano Buti

Showing results (191-200 of 336) with videos related to

Pageof 34
Sort By:
Chinese Clinical Oncology|September 2, 2025
New hormonal agents and integrated strategies for non-metastatic, hormone-sensitive prostate carcinoma: the orphan setting?-a narrative reviewFabrizio Di Costanzo, Iolanda Santa Parisi, Giuseppe Neola, et al.
Anti-Cancer Drugs|December 20, 2022
The impact of proton-pump inhibitors administered with tyrosine kinase inhibitors in patients with metastatic renal cell carcinomaSebastiano Buti, Chiara Tommasi, Giulia Scartabellati, et al.
Cancer Treatment and Research Communications|November 3, 2019
Treatment Outcome of metastatic lesions from renal cell carcinoma underGoing Extra-cranial stereotactic body radioTHERapy: The together retrospective studySebastiano Buti, Melissa Bersanelli, Alessandro Viansone, et al.
Clinical Genitourinary Cancer|January 22, 2017
First-Line PAzopanib in NOn-clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA StudySebastiano Buti, Melissa Bersanelli, Francesca Maines, et al.
World Journal of Clinical Oncology|December 15, 2021
First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case seriesSebastiano Buti, Melissa Bersanelli, Francesco Massari, et al.
Scientific Reports|February 28, 2024
Instrumental activities of daily living in older patients with metastatic prostate cancer: results from the meet-URO network ADHERE prospective studyLucia Fratino, Jerry Polesel, Emilio Francesco Giunta, et al.
Tumori|May 4, 2026
International multicenter experience of prognostic factors and treatment outcomes of metastatic non-clear cell renal cell carcinomaAlessandro Rametta, Sebastiano Buti, Marco Stellato, et al.
Therapeutic Advances in Urology|July 26, 2023
The role of mean corpuscular volume and red cell distribution width in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: the MARECAP retrospective studyChiara Tommasi, Giulia Scartabellati, Diana Giannarelli, et al.
Targeted Oncology|August 2, 2021
Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World StudyMatteo Santoni, Francesco Massari, Enrique Grande, et al.
Targeted Oncology|January 7, 2015
Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapyMatteo Santoni, Sebastiano Buti, Alessandro Conti, et al.
Pageof 34

Showing results (191-200 of 336) with videos related to

Sort By:
Pageof 34
Chinese Clinical Oncology|September 2, 2025
New hormonal agents and integrated strategies for non-metastatic, hormone-sensitive prostate carcinoma: the orphan setting?-a narrative reviewFabrizio Di Costanzo, Iolanda Santa Parisi, Giuseppe Neola, et al.
Anti-Cancer Drugs|December 20, 2022
The impact of proton-pump inhibitors administered with tyrosine kinase inhibitors in patients with metastatic renal cell carcinomaSebastiano Buti, Chiara Tommasi, Giulia Scartabellati, et al.
Cancer Treatment and Research Communications|November 3, 2019
Treatment Outcome of metastatic lesions from renal cell carcinoma underGoing Extra-cranial stereotactic body radioTHERapy: The together retrospective studySebastiano Buti, Melissa Bersanelli, Alessandro Viansone, et al.
Clinical Genitourinary Cancer|January 22, 2017
First-Line PAzopanib in NOn-clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA StudySebastiano Buti, Melissa Bersanelli, Francesca Maines, et al.
World Journal of Clinical Oncology|December 15, 2021
First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case seriesSebastiano Buti, Melissa Bersanelli, Francesco Massari, et al.
Scientific Reports|February 28, 2024
Instrumental activities of daily living in older patients with metastatic prostate cancer: results from the meet-URO network ADHERE prospective studyLucia Fratino, Jerry Polesel, Emilio Francesco Giunta, et al.
Tumori|May 4, 2026
International multicenter experience of prognostic factors and treatment outcomes of metastatic non-clear cell renal cell carcinomaAlessandro Rametta, Sebastiano Buti, Marco Stellato, et al.
Therapeutic Advances in Urology|July 26, 2023
The role of mean corpuscular volume and red cell distribution width in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: the MARECAP retrospective studyChiara Tommasi, Giulia Scartabellati, Diana Giannarelli, et al.
Targeted Oncology|August 2, 2021
Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World StudyMatteo Santoni, Francesco Massari, Enrique Grande, et al.
Targeted Oncology|January 7, 2015
Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapyMatteo Santoni, Sebastiano Buti, Alessandro Conti, et al.
Pageof 34